Gilead monopoly blocks cryptococcal meningitis treatment for people living with HIV

Posted on


Cryptococcal meningitis

People living with HIV (PLHIV), health workers, academics, researchers, and treatment providers agree that one of the biggest programmatic challenges of the HIV response today is how programmes should address treatment failure, delayed initiation, and treatment interruption: all of which lead to advanced  HIV disease. Severe bacterial and fungal infections are – next to TB – the leading causes of morbidity and mortality among PLHIV.  

Civil society has been battling for many years for increased access to liposomal amphotericin B (L-AmB),  an antifungal medicine produced by the American pharmaceutical corporation, Gilead As a result of  Gilead’s monopoly control of the price as well as supply through both exclusive sourcing of components as well as being the only company to achieve WHO requirements, we’re now facing a situation of shortage of L-AmB. L-AmB is used (together with other essential antifungals, such as flucytosine and fluconazole) to treat cryptococcal meningitis (CM), a fungal brain infection that particularly affects PLHIV.  

After all these years, these medicines are still only available in a handful of countries – and where they  are available, they are often unaffordable. Some of these medicines are also used for other neglected  diseases such as kala- azar. Now there is even more pressure on their global supply, especially for L-AmB,  given the urgent needs of people affected by COVID-19 and its associated black fungus (mucormycosis) outbreak in India and Nepal.

Cryptococcal meningitis infographic

Cryptococcal Disease and Treatment Access: FAQs and key messages to Gilead

Cryptococcal meningitis is a painful opportunistic infection, most commonly affecting people living  with advanced HIV. Effective treatments exist and rely on three key medicines: fluconazole,  flucytosine and liposomal amphotericin B (L-AmB). Unfortunately, for several reasons, L-AmB is not as  widely accessible as needed. As an international medical humanitarian organisation, Médecins Sans  Frontières (MSF) relies on access to L-AmB to treat cryptococcal meningitis and other diseases. Like  many other treatment providers, MSF has experienced challenges accessing affordable L-AmB.  

These frequently asked questions explain what cryptococcal meningitis is, why L-AmB is needed for  treatment, what the access challenges are, and what Gilead should do to improve access as the  manufacturer of the only quality-assured version of L-AmB currently available. 

What is advanced HIV and how is it diagnosed? 

People living with HIV are still dying of AIDS, also referred to as advanced HIV. World Health  Organization (WHO) 2017 guidelines on managing advanced HIV disease state the following criteria  for people living with HIV to be considered to have advanced HIV:(1) 

For adults, adolescents, and children five years or older, advanced HIV is defined as a CD4 cell count <200 cells/mm3 or a WHO clinical stage (3 or 4) diagnosis at presentation for care. All children with HIV who are younger than five years old should be considered as having advanced disease at presentation for care. 

CD4 testing is needed to diagnose advanced HIV, yet people in 12 African countries have limited or no access to routine CD4 testing.(2) 

What is cryptococcal meningitis? 

Cryptococcal meningitis is a painful fungal infection of the brain and surrounding membranes occurring primarily among people with advanced HIV (as an ‘opportunistic infection’). Responsible for about 14% of AIDS-related deaths worldwide, it is second only to tuberculosis as a cause of death for  people living with HIV.(3)

What is the global burden of cryptococcal meningitis? 

While Sub-Saharan African countries have the highest burden of cryptococcal meningitis, it is also  common in those with advanced HIV in Asia and is responsible for the largest proportion of AIDS related deaths in Central and South America. 

Among people living with HIV globally in 2020, an estimated 174,500 had the cryptococcal antigen (CrAg+), an estimated 108,000 of whom had cryptococcal meningitis.(3)

What are the global guidelines on screening for cryptococcal disease? 

The WHO 2017 advanced HIV disease guidelines and 2018 guidelines on cryptococcal disease recommend that everyone with advanced HIV should be screened for cryptococcal antigen using the cryptococcal antigen test.(1,4) 

When cryptococcal antigen screening is positive, people should ideally proceed to have a lumbar puncture to determine whether full or pre-emptive treatment is needed, as recommended in the  WHO 2018 cryptococcal disease guidelines.(4)

What are the global guidelines on prevention of cryptococcal disease? 

When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should be given  to adults and adolescents living with HIV who have a CD4 cell count <100 cells/mm3 and may be  considered for those with a CD4 cell count <200 cells/mm. (3) Similarly, if after a positive cryptococcal  antigen test the next step of a lumbar puncture is negative (or not available), fluconazole is  recommended for pre-emptive treatment.

What are the global guidelines on treatment of cryptococcal disease?  

Cryptococcal disease can be treated with amphotericin B, which is available in conventional and  liposomal formulations. Studies have shown conventional and liposomal amphotericin B to have  equivalent efficacy at treating cryptococcal meningitis.(5,6) However, the liposomal formulation is less  toxic (especially for the kidneys) and therefore easier to give to people needing treatment, especially  in settings with limited capacity for monitoring.  

The WHO 2018 guidelines on cryptococcal disease recommend a one-week regimen with conventional  amphotericin B and flucytosine, followed by one week of fluconazole.(4) One of the reasons that WHO  does not insist on liposomal amphotericin B (L-AmB) in its recommendations is the difficulty in  procuring it and the high price.  

What is the AMBITION trial?  

The AMBITION trial, coordinated by The London School of Hygiene and Tropical Medicine, tested the  efficacy and the safety of using a single high dose of L-AmB co-administered with flucytosine as the  initial treatment for cryptococcal meningitis.  

Participants were recruited in African collaborating institutions in conjunction with local hospitals in  the following countries: Botswana, Malawi, South Africa, Uganda and Zimbabwe. 

The results of the AMBITION trial will be presented at the 2021 International AIDS Society conference.  If the results are positive, the regimen would be an opportunity to make cryptococcal meningitis  treatment simpler and safer, potentially reducing the number of days required for inpatient admission  and reducing the overall costs of treating cryptococcal meningitis.  

What are the barriers preventing people with cryptococcal meningitis from accessing L-AmB? 

Gilead’s L-AmB product, marketed as Ambisome, is the only quality-assured L-AmB product available  in the market.  

Although generic companies have been working for years to develop L-AmB, they face multiple  hurdles. L-AmB is not patented, but Gilead has long hidden the liposomal technology – a key  component of manufacturing L-AmB – as a trade secret. This, combined with limited availability of raw  materials and challenging regulatory pathways, has significantly delayed generic competition.  

The absence of generic manufacturers has resulted in a lack of sustainable supply of L-AmB. Access to  L-AmB also remains extremely limited in low- and middle-income countries (LMICs) for several  additional reasons: 

Gilead has failed to provide sufficient access to the treatment at the ‘access price’ of US$16.25  promised for 116 countries, as announced in September 2018.(7) For example, although India and  South Africa are on the list of the countries eligible for Gilead’s access price, the treatment is not  easily available at that price in either country. Gilead is not the market authorisation holder in  these countries. Instead they signed exclusive license distribution agreements with local suppliers,  leaving these countries’ prices set by Gilead’s marketing partners. The price of L-AmB in these  markets can range between $70-205 per vial,(8) and local suppliers are reluctant to fulfil Gilead’s  obligation to supply L-AmB at the access price.(9)

•The price of L-AmB is high in the private market in LMICs ($70-200 per vial).  Gilead has failed to register L-AmB in some of the 116 countries eligible for the access price  announced in September 2018.(b)

There is insufficient funding for cryptococcal meningitis treatment programmes because it is neglected, and not always prioritised by donors and governments due to high prices. 

Due to unaffordable prices or limited availability because of a lack of registration, L-AmB is inaccessible for most countries with high burdens of cryptococcal meningitis. Many ministries of  health have not included it into their national guidelines for treatment of cryptococcal meningitis.

Is there a generic version of L-AmB in the pipeline?  

MSF has tried several times to find a generic source of L-AmB. Some generic companies registered the  product but never put it into production. Other generic sources faced quality assurance challenges  due to a lack of appropriate regulatory guidance from WHO and national medicines regulatory  authorities (NMRAs). The mucormycosis outbreak in India and increased demand for generic versions  of L-AmB has led to generic companies entering the supply chain and approaching India’s NMRA for  approval. These new sources are yet to be WHO pre-qualified and made available for supply to other countries. Many public health actors are working to address both WHO prequalification and  international supply and looking into how a generic source of L-AmB can be made available as a long term solution.

What does Gilead need to do to improve access to this lifesaving treatment? 

As the supplier of the only quality-assured L-AmB product currently available, two actions Gilead  should immediately take to improve access to L-AmB are: 

• Fulfil a nearly three-year-old promise of a $16.25 per vial price for L-AmB for 116 countries to  treat cryptococcal meningitis, extend this price for L-AmB to treat mucormycosis, and  prioritise registering L-AmB in these countries; and  

• Prioritise manufacturing and supply of L-AmB to meet increasing global demands for  mucormycosis treatment, ongoing needs for visceral leishmaniasis treatment, and cryptococcal meningitis treatment needs.  



1 WHO. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. [Online]. 2017 [Cited 2021 Jul 12].  Available from: 2 Ending Cryptococcal Meningitis Deaths by 2030 – Strategic Framework. South Africa. [Online]. 2021 [Cited 2021 Jul 12]. Available from: strategic%20framework_ENG_14.5.2021.pdf 

3 Rajasingham R. The global burden of HIV-associated cryptococcal infection: 2020 edition. [Powerpoint presentation]. Ending Cryptococcal  Meningitis Deaths by 2030 – A New Global Initiative. Advanced HIV Disease Series. 2021 May 12 [Cited 2021 Jul 12]. Available from: 

4 WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children.  [Online]. 2018 [Cited 2021 Jul 21]. Available from: eng.pdf;jsessionid=3DD47D6B4F06AFA32280E2048900A316?sequence=1 

5 Leenders A, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral  fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. [Online]. 1997 [Cited 2021 Jul 13]; 11(12). Available from:  

6 Hamill R, Sobel J, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for  treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis.  [Online]. 2010 [Cited 2021 Jul 13]; 51(2). Available from: 

7 Gilead Sciences announces steep discounts for Ambisome to treat cryptococcal meningitis in low- and middle-income countries. Press  release. [Online]. 2018 Sep 7 [cited 2021 Jul 8]. Available from: for-ambisome 

8 Medicine Prices. What should your medicines cost? [Online]. 2020 [Cited 2021 Jul 12]. Available from: 

9 MSF. Untangling the web: HIV medicine pricing and access issues, 2020. [Online]. 2020 [Cited 2021 Jul 12]. Available from:

This originally appeared on MSF